Last reviewed · How we verify
RAY1225
RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways.
RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways. Used for FGFR-altered solid tumors (Phase 3 development).
At a glance
| Generic name | RAY1225 |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RAY1225 targets FGFR-driven oncogenic signaling in tumors with FGFR alterations. By inhibiting FGFR kinase activity, the drug blocks downstream proliferation and survival signals in cancer cells dependent on aberrant FGFR signaling, particularly in solid tumors with FGFR mutations or fusions.
Approved indications
- FGFR-altered solid tumors (Phase 3 development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants (PHASE1)
- The Safety, Tolerability and Pharmacokinetic Study of RAY1225 (PHASE1)
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (PHASE1)
- A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes (PHASE3)
- A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (PHASE3)
- A Study of RAY1225 in Participants With Type 2 Diabetes (PHASE2)
- Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight (PHASE3)
- A Study of RAY1225 in Participants With Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAY1225 CI brief — competitive landscape report
- RAY1225 updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI